Production and Immunogenicity Assessment of LTp50: An Escherichia coli-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein.

Publication date: Feb 27, 2024

Subunit vaccines stand as a leading approach to expanding the current portfolio of vaccines to fight against COVID-19, seeking not only to lower costs but to achieve long-term immunity against variants of concern and have the main attributes that could overcome the limitations of the current vaccines. Herein a chimeric protein targeting S1 and S2 epitopes, called LTp50, was designed as a convenient approach to induce humoral responses against SARS-CoV-2. LTp50 was produced in recombinant Escherichia coli using a conventional pET vector, recovering the expected antigen in the insoluble fraction. LTp50 was purified by chromatography (purity > 90%). The solubilization and refolding stages helped to obtain a stable protein amenable for vaccine formulation. LTp50 was adsorbed onto alum, resulting in a stable formulation whose immunogenic properties were assessed in BALB/c mice. Significant humoral responses against the S protein (BA. 5 variant) were detected in mice subjected to three subcutaneous doses (10 ug) of the LTp50/alum formulation. This study opens the path for the vaccine formulation optimization using additional adjuvants to advance in the development of a highly effective anti-COVID-19 vaccine directed against the antigenic regions of the S protein, which are less prone to mutations.

Open Access PDF

Concepts Keywords
Chromatography built-in adjuvant
Mice chimeric antigen
Recovering COVID-19
Vaccines humoral response
linear epitopes


Type Source Name
disease IDO production
disease MESH COVID-19
disease VO vaccine
disease VO effective
disease VO COVID-19 vaccine
disease MESH Comas
drug DRUGBANK Coenzyme M
disease VO organization
disease MESH Emergency
disease MESH long COVID
disease VO population
disease VO dose
drug DRUGBANK Amino acids
disease VO COVAXIN
disease VO KCONVAC
disease VO Abdala
disease VO Soberana 02
disease VO Corbevax
disease VO QazVac
disease VO EpiVacCorona
disease VO vaccination
disease VO VAT00002
disease MESH Allergy
disease MESH Infectious Diseases
disease VO efficiency
drug DRUGBANK Aspartame
disease VO vaccine candidate
disease MESH seroconversion
disease VO Nanocovax
disease MESH infection
disease VO ZF2001
disease VO effectiveness
drug DRUGBANK Clostridium tetani toxoid antigen (formaldehyde inactivated)
disease IDO host
disease VO viable
drug DRUGBANK Nonoxynol-9
disease IDO enterotoxin
disease VO report
disease IDO cell
drug DRUGBANK Glycine
drug DRUGBANK Serine
drug DRUGBANK Proline
disease VO efficient
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Phosphate ion
drug DRUGBANK Urea
disease IDO process
disease IDO endotoxin
drug DRUGBANK Imidazole
drug DRUGBANK Oxygen
drug DRUGBANK Sucrose
disease VO immunization
disease VO titer
disease VO immunized
disease IDO assay
disease VO Lentivirus
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Piroxicam
disease VO storage
disease VO time
pathway REACTOME Signal Transduction
pathway KEGG Endocytosis
disease MESH hepatitis
pathway KEGG Viral replication
disease IDO pathogen
disease MESH antibody dependent enhancement
disease MESH death
disease VO Canada
drug DRUGBANK Ampicillin
drug DRUGBANK Chloramphenicol
disease VO volume
drug DRUGBANK Lactose
drug DRUGBANK Iron
disease VO protocol
disease MESH shock
drug DRUGBANK Tromethamine
drug DRUGBANK Water
disease VO device
disease VO USA
drug DRUGBANK Sodium carbonate
drug DRUGBANK Glycerin
disease IDO blood
drug DRUGBANK Carbonate ion
drug DRUGBANK Sodium bicarbonate
drug DRUGBANK Citric Acid
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Tocopherol
drug DRUGBANK Squalene
disease VO Primates
disease VO subunit vaccine
disease VO Betacoronavirus
disease VO conjugate vaccine
disease VO peptide vaccine
drug DRUGBANK Aluminum hydroxide
disease MESH SD1
disease VO Bacteria
drug DRUGBANK Aluminium
disease MESH viral infections
disease VO AdCOVID
drug DRUGBANK Formaldehyde
disease VO inactivated vaccine
disease MESH cholera

Original Article

(Visited 1 times, 1 visits today)